v3.25.2
SEGMENT INFORMATION - Company`S Segment, Including Segment Expenses, and A Reconciliation to Net Income (Loss) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting Information [Line Items]            
Total revenues $ 611,091   $ 362,931   $ 1,355,947 $ 776,395
Segment expenses and other segment items            
Cost of sales (excluding amortization of in-licensed rights) 152,558   44,545   290,122 95,104
Selling, general and administrative- other (excluding non-cash items) 137,897   138,796   271,526 265,799
(Gain) loss on strategic investments (36,721)   (148)   54,007 (1,079)
Interest expense 5,228   4,832   9,731 8,998
Interest income 5,254   8,076   15,444 15,169
Income tax (benefit) expense (43,254)   7,117   20,736 12,446
Depreciation and amortization expense         20,818 17,463
Stock-based compensation expense         78,453 91,174
Segment net income (loss) 196,892 $ (447,508) 6,460 $ 36,119 (250,616) 42,579
Reconciliation of profit or loss            
Adjustments and reconciling items 0   0   0 0
Consolidated net income (loss) 196,892 $ (447,508) 6,460 $ 36,119 (250,616) 42,579
Operating Segments [Member]            
Segment Reporting Information [Line Items]            
Total revenues 611,091   362,931   1,355,947 776,395
Segment expenses and other segment items            
Cost of sales (excluding amortization of in-licensed rights) 152,558   44,545   290,122 95,104
Compensation and other personnel expenses 89,839   77,535   182,923 161,122
Up-front and milestone expenses 0   0   583,787 0
Manufacturing expenses 80,685   50,659   148,150 120,359
Clinical trial expenses 33,511   39,861   66,658 84,008
Facility- and technology-related expenses (excluding depreciation and amortization) 28,580   26,651   56,237 51,629
Research and development- other (excluding non-cash items) [1] 31,843   27,646   60,314 56,494
Selling, general and administrative- other (excluding non-cash items) [2] 56,322   55,474   107,464 104,436
Roche collaboration reimbursement (25,689)   (17,940)   (54,170) (39,598)
Other segment items [3] (1,314)   (10,886)   (3,223) (13,571)
(Gain) loss on strategic investments (36,721)   (148)   54,007 (1,079)
Interest expense 5,228   4,832   9,731 8,998
Interest income (5,254)   (8,076)   (15,444) (15,169)
Income tax (benefit) expense (43,254)   7,117   20,736 12,446
Depreciation and amortization expense 10,840   8,719   20,818 17,463
Stock-based compensation expense 37,025   50,482   78,453 91,174
Segment net income (loss) 196,892   6,460   (250,616) 42,579
Reconciliation of profit or loss            
Consolidated net income (loss) $ 196,892   $ 6,460   $ (250,616) $ 42,579
[1] Research and development-other includes professional services, pre-clinical expenses and research and other expenses.
[2] Selling, general and administrative-other includes professional services and other expenses.
[3] Other segment items included in segment net income (loss) include accretion of investment discount, net, change in fair value of derivatives and other, net, as well as the items separately presented and not defined as significant expenses below.